Characterizing ligand-gated ion channel receptors with genetically encoded Ca++ sensors

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Yamauchi, John G ^a,b   Nemecz, Ákos ^a,b   Nguyen, Quoc Thang ^b,d   Muller, Arnaud ^b   Schroeder, Lee F ^b   Talley, Todd T ^a   Lindstrom, Jon ^c   Kleinfeld, David ^b   Taylor, Palmer ^a  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NeurAccel Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIBATIDINE; ION CHANNEL; LIGAND GATED ION CHANNEL; LIGAND GATED ION CHANNEL RECEPTOR; METHYLLYCACONITINE; N (5 CHLORO 2,4 DIMETHOXYPHENYL) N' (5 METHYL 3 ISOXAZOLYL)UREA; NEURONAL CALCIUM SENSOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; ONDANSETRON; RECEPTOR; SEROTONIN; SEROTONIN 3A RECEPTOR; UNCLASSIFIED DRUG; CALCIUM; LIGAND; NICOTINIC RECEPTOR; SEROTONIN RECEPTOR;

ACETYLCHOLINE RELEASE; ARTICLE; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DESENSITIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC CODE; HUMAN; HUMAN CELL; NEUROTRANSMISSION; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; VALIDATION PROCESS; ANIMAL; CELL LINE; CHANNEL GATING; DOSE RESPONSE; GENETIC PROCEDURES; METABOLISM; METHODOLOGY; MOUSE;

ANIMALS; BIOSENSING TECHNIQUES; CALCIUM; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; ION CHANNEL GATING; LIGAND-GATED ION CHANNELS; LIGANDS; MICE; RECEPTORS, NICOTINIC; RECEPTORS, SEROTONIN;

EID: 79551515778     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016519     Document Type: Article

References (42)

1. Hogg RC, Raggenbass M, Bertrand D (2003) Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol 147: 1-46.
2. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, et al. (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
3. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29: 8805-8815.
4. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, et al. (2007) Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol 17: 145-155.
5. Newhouse PA, Potter A, Levin ED (1997) Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 11: 206-228.
6. Warpman U, Nordberg A (1995) Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 6: 2419-2423.
7. Salminen O, Murphy KL, McIntosh JM, Drago J, Marks MJ, et al. (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol 65: 1526-1535.
8. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, et al. (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436: 103-107.
9. Taly A, Corringer P-J, Guedin D, Lestage P, Changeux J-P (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8: 733-750.
10. Arneric SP, Holladay M, Williams M (2007) Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 74: 1092-1101.
11. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R (2008) High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 7: 358-368.
12. Sidach SS, Fedorov NB, Lippiello PM, Bencherif M (2009) Development and optimization of a high-throughput electrophysiology assay for neuronal alpha4beta2 nicotinic receptors. J Neurosci Methods 182: 17-24.
13. Dunlop J, Roncarati R, Jow B, Bothmann H, Lock T, et al. (2007) In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74: 1172-1181.
14. Fitch RW, Xiao Y, Kellar KJ, Daly JW (2003) Membrane potential fluorescence: a rapid and highly sensitive assay for nicotinic receptor channel function. Proc Natl Acad Sci U S A 100: 4909-4914.
15. Baubet V, Le Mouellic H, Campbell AK, Lucas-Meunier E, Fossier P, et al. (2000) Chimeric green fluorescent protein-aequorin as bioluminescent Ca2+reporters at the single-cell level. Proc Natl Acad Sci U S A 97: 7260-7265.
16. Drobac E, Tricoire L, Chaffotte AF, Guiot E, Lambolez B (2010) Calcium imaging in single neurons from brain slices using bioluminescent reporters. J Neurosci Res 88: 695-711.
17. Kleinfeld D, Griesbeck O (2005) From art to engineering? The rise of in vivo mammalian electrophysiology via genetically targeted labeling and nonlinear imaging. PLoS Biol 3: e355.
18. Mank M, Griesbeck O (2008) Genetically encoded calcium indicators. Chem Rev 108: 1550-1564.
19. Miyawaki A (2005) Innovations in the imaging of brain functions using fluorescent proteins. Neuron 48: 189-199.
20. Mank M, Santos AF, Direnberger S, Mrsic-Flogel TD, Hofer SB, et al. (2008) A genetically encoded calcium indicator for chronic in vivo two-photon imaging. Nature Methods 5: 805-811.
21. Nguyen Q-T, Schroeder LF, Mank M, Muller A, Taylor P, et al. (2009) An in vivo biosensor for neurotransmitter release and in situ receptor activity. Nature Neuroscience 13: 127-132.
22. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, et al. (1993) Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366: 479-483.
23. Craig P, Bose S, Zwart R, Beattie R, Folly E, et al. (2004) Stable expression and characterisation of a human a7 nicotinic subunit chimera: a tool for functional high-throughput screening. Eur J Pharmacol 502: 31-40.
24. Rayes D, Spitzmaul G, Sine SM, Bouzat C (2005) Single-channel kinetic analysis of chimeric alpha7-5HT3A receptors. Mol Pharmacol 68: 1475-1483.
25. Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254: 432-437.
26. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, et al. (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397: 359-363.
27. Papke R, Schiff H, Jack B, Horenstein N (2005) Molecular dissection of tropisetron, an a7 nicotinic acetylcholine receptor-selective partial agonist. Neuroscience Letters 378: 140-144.
28. Bouzat C, Bartos M, Corradi J, Sine SM (2008) The interface between extracellular and transmembrane domains of homomeric Cys-loop receptors governs open-channel lifetime and rate of desensitization. J Neurosci 28: 7808-7819.
29. Roncarati R, Seredenina T, Jow B, Jow F, Papini S, et al. (2008) Functional properties of a7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. ASSAY Drug Dev Technol 6: 181-193.
30. Bertrand D, Gopalakrishnan M (2007) Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74: 1155-1163.
31. Young GT, Zwart R, Walker AS, Sher E, Millar NS (2008) Potentiation of 7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A 105: 14686-14691.
32. Sine S, Taylor P (1979) Functional consequences of agonist-mediated state transitions in the cholinergic receptor. Studies in cultured muscle cells. J Biol Chem 254: 3315-3325.
33. Davies AR, Hardick DJ, Blagbrough IS, Potter BV, Wolstenholme AJ, et al. (1999) Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacol 38: 679-690.
34. Sine SM, Taylor P (1981) Relationship between reversible antagonist occupancy and the functional capacity of the acetylcholine receptor. J Biol Chem 256: 6692-6699.
35. Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. Mol Pharmacol 68: 1839-1851.
36. Kelley SP, Dunlop JI, Kirkness EF, Lambert JJ, Peters JA (2003) A cytoplasmic region determines single-channel conductance in 5-HT3 receptors. Nature 424: 321-324.
37. Taylor P, Insel PA (1990) Molecular basis of pharmacologic selectivity. Chapter 1. In: Pratt WB, Taylor P, eds. Principles of drug action: the basis of pharmacology 3rd Ed 3rd ed. New York: Churchill Livingstone. pp 1-102.
38. Wyllie DJA, Chen PE (2009) Taking the time to study competitive antagonism. Br J Pharmacol 150: 541-551.
39. Chavez-Noriega LE, Gillespie A, Stauderman KA, Crona JH, Claeps BO, et al. (2000) Characterization of the recombinant human neuronal nicotinic acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in HEK293 cells. Neuropharmacol 39: 2543-2560.
40. Kuryatov A, Onksen J, Lindstrom J (2008) Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol 74: 132-143.
41. Rizzi JP, Nagel AA, Rosen T, McLean S, Seeger T (1990) An initial threecomponent pharmacophore for specific serotonin-3 receptor ligands. J Med Chem 33: 2721-2725.
42. Rosen T, Nagel AA, Rizzi JP, Ives JL, Daffeh JB, et al. (1990) Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists. J Med Chem 33: 2715-2720.